December 27, 2014 7:46 PM ET

Biotechnology

Company Overview of aTyr Pharma Inc.

Company Overview

aTyr Pharma Inc., a protein therapeutics company, engages in the discovery and development of biologic therapeutics based on physiocrines. It focuses on the discovery of phyisiocrines, which are a class of endogenous human proteins from amino acyl tRNA synthetases that function as extracellular signaling molecules in various physiologic settings; and the development of physiocrine-based medicines for indications in the areas of hematology, immune modulation, infection, and metabolism. The company’s lead product is Tmax, which is in preclinical development for thrombocytopenia. aTyr Pharma Inc. was incorporated in 2005 and is based in San Diego, California.

3565 General Atomics Court

Suite 103

San Diego, CA 92121

United States

Founded in 2005

Phone:

858-731-8389

Fax:

858-731-8394

Key Executives for aTyr Pharma Inc.

Executive Chairman and Chief Executive Officer
Age: 54
President and Chief Operating Officer
Founder and Director
Age: 73
Chief Medical Officer
Associate Director of Discovery Research
Compensation as of Fiscal Year 2014.

aTyr Pharma Inc. Key Developments

aTyr Pharma Appoints Fred Ramsdell as Vice President, Immunology

aTyr Pharma announced that Fred Ramsdell, Ph.D., joined aTyr as Vice President, Immunology. Prior to joining aTyr, Dr. Ramsdell helped establish the immunobiology research strategy for both Darwin Molecular and NovoNordisk. While at Celltech he led research efforts resulting in the discovery of Foxp3, a critical gene for normal immune function, the absence of which results in a rare but fatal autoimmunity in humans, and contributed to the identification and development of sclerostin, the target of a Phase III clinical program at Amgen/UCB.

aTyr Pharma Inc. Presents at Boston Biotech NY/NJ CEO Conference, Nov-12-2014 10:05 AM

aTyr Pharma Inc. Presents at Boston Biotech NY/NJ CEO Conference, Nov-12-2014 10:05 AM. Venue: Apella, 450 East 29th Street, New York, New York, United States. Speakers: John Mendlein.

aTyr Pharma Inc. Appoints John C. Mckew as Vice President of Research

aTyr Pharma Inc. announced that John C. McKew, joined the company as vice president of research. Dr. McKew brings more than two decades of expertise in translational research, including key leadership positions at the National Institutes of Health, Wyeth Research and Genetics Institute Inc. (prior to its acquisition by Wyeth). Dr. McKew will lead the company's efforts to expand and translate its novel Physiocrine biology into meaningful therapeutics to treat rare, grave immune-driven disorders. Dr. McKew most recently served as the acting scientific director of the Division of Preclinical Innovation at the National Center for Advancing Translational Sciences (NCATS) within the National Institutes of Health. His responsibilities included developing both the Therapeutics for Rare and Neglected Disease (TRND) and the Bridging Interventional Development Gaps (BrIDGs) programs.

Similar Private Companies By Industry

Company Name Region
MesoBio LLC United States
Aventis Bio-Services Inc. United States
Heparinex LLC United States
Open Monoclonal Technology, Inc. United States
Aequor, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact aTyr Pharma Inc., please visit www.atyrpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.